Clinical trials: Skin Diseases, Papulosquamous
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
The primary objectives of this study are to assess whether there is transfer of Certolizumab Pegol (CZP) into breast milk of lactating mothers who are receiving an established dosing regimen of CZP by evaluating the concentration…
- Conditions
- Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- CRADLE (NCT02154425)
- Testing
- Breast milk sampling, Certolizumab Pegol
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 17 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Plaque Psoriasis, Psoriatic Arthritis
Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)
Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy.
- Conditions
- Plaque Psoriasis, Psoriatic Arthritis, Scalp Psoriasis, Nail Psoriasis
- Trial name
- NCT06802848
- Testing
- Xeligekimab injection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chongqing Genrix Biopharmaceutical Co., Ltd
Psoriasis
The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment
This study aims to see if patient quality of life can be approved after treatment with an injectable medication called ustekinumab for the treatment of generalized psoriasis.
- Trial name
- NCT01511315
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Francisco
Psoriasis Vulgaris
Low-Salt Diet Effect on Th17-Mediated Inflammation and Vascular Reactivity in Psoriasis
Psoriasis presents an independent cardiovascular risk factor characterized by chronic low-grade systemic inflammation and oxidative stress which altogether might lead to endothelial dysfunction.
- Trial name
- NCT05892640
- Testing
- Low-Salt Diet
- Where
- Croatia
- Volunteers
- 50 people
- Sponsor
- Josip Juraj Strossmayer University of Osijek
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Palmoplantar Psoriasis
Efficacy Study of TEPSO® Socks in Improving Palmoplantar Psoriasis
The purpose of this study is to evaluate the efficacy of a special sock, manufactured using TEPSO®, compared to a normal cotton sock in the prognosis of symmetrical palmoplantar psoriasis present for at least one year.
- Trial name
- NCT01197976
- Testing
- TEPSO cloth, Standard cloth
- Where
- 3 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Lenzi Egisto S.P.A.
Psoriasis
Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis
There is an unmet medical need for safe, effective oral therapy for moderate-to-severe psoriasis. CC-10004 will be evaluated in a controlled setting of a clinical study.
- Trial name
- PSOR-003 (NCT00606450)
- Testing
- CC-10004
- Where
- 31 sites in Canada, Czechia and 1 more
- Volunteers
- 260 people
- Sponsor
- Amgen
Potentially Malignant Lesions, Oral Lichen Planus
Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
The aim of this study is to evaluate salivary expression of lncRNA DQ786243 as a potential marker for diagnosis of oral potentially malignant lesions compared to normal controls and its effect on salivary expression of miRNA146a.
- Conditions
- Potentially Malignant Lesions, Oral Lichen Planus, Leukoplakia, Oral
- Trial name
- NCT05730855
- Testing
- Real-time Polymerase Chain Reaction technique
- Where
- Egypt
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Fayoum University
Psoriatic Arthritis
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
This study will assess the efficacy and safety of secukinumab in patients with active psoriatic arthritis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.
- Trial name
- FUTURE 1 (NCT01392326)
- Testing
- Secukinumab (75 mg), Secukinumab (150 mg)
- Where
- 110 sites in United States, Argentina and 17 more
- Volunteers
- 606 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT00646191
- Testing
- adalimumab
- Volunteers
- 137 people
- Sponsor
- Abbott
Psoriasis (PsO), Traditional Chinese Medicine (TCM)
Research on the Extraction of Tongue and Facial Diagnosis Features of Psoriasis Vulgaris in Traditional Chinese Medicine and Its Correlation With Laboratory Indicators
Psoriasis Vulgaris is a chronic, inflammatory, and immune-activated skin disease. It is the most common type of psoriasis, accounting for approximately 85-90% of all psoriasis patients.
- Conditions
- Psoriasis (PsO), Traditional Chinese Medicine (TCM), Diagnosis
- Trial name
- NCT07351448
- Testing
- No intervention
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Psoriasis, Atopic Dermatitis
Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents
Psoriasis is a common inflammatory disease of the skin and joints with a prevalence of 1-3% in the caucasian population of Northern Europe and the US.
- Conditions
- Psoriasis, Atopic Dermatitis, Atherosclerosis
- Trial name
- NCT01356758
- Testing
- biological treatment
- Where
- Denmark
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Psoriasis
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
The investigators propose to improve the possibility of reaching skin resolution by identifying certain markers or gene patterns that may predict patient response to certain psoriasis drugs ahead of time, thus eliminating or…
- Trial name
- NCT05270733
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University Hospitals Cleveland Medical Center
Arthritis, Rheumatoid, Crohn Disease
A Long-term Safety Study of Infliximab (Remicade)
This is a study evaluating the long-term safety of infliximab (Remicade)
- Conditions
- Arthritis, Rheumatoid, Crohn Disease, Psoriasis
- Trial name
- NCT00261976
- Testing
- Infliximab (Remicade)
- Where
- 205 sites in United States, Argentina and 17 more
- Volunteers
- 2,971 people
- Sponsor
- Centocor, Inc.
Lichen Planus Scalp, Lichen Planus
Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris
To evaluate the safety and efficacy of ixekizumab in lichen planus and lichen planopilaris clinical response by Total Body Surface (TBS) determination, Investigator Global Assessment (IGA) Score, Lichen Planopilaris Activity…
- Conditions
- Lichen Planus Scalp, Lichen Planus, Lichen Planopilaris
- Trial name
- NCT05030415
- Testing
- Ixekizumab Auto-Injector
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of New Mexico
Oral Lichen Planus
The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus
This study was initiated to evaluate the potential of dietary supplementation of omega-3 for providing an inexpensive, safe and effective therapeutic agent for managing atrophic/erosive lichen planus.
- Trial name
- NCT02106468
- Testing
- Prednisone tablet 5mg, Omega-3 soft capsules 1000 mg
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- October 6 University
Atopic Dermatitis, Ichthyosis
Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments
This is designated to validate patient-reported outcomes (PRO) measures in itch-specific pediatric skin conditions, such as atopic dermatitis, and examine the ability of a modified stigma instrument to assess the severity and…
- Conditions
- Atopic Dermatitis, Ichthyosis, Psoriasis
- Trial name
- NCT03051347
- Testing
- Itch Questionnaire and Interview, Stigma Questionnaire and Interview, Cognitive Interview and PROMIS Itch Questionnaire
- Where
- United States
- Volunteers
- 943 people
- Sponsor
- Northwestern University
Oral Lichen Planus
Evaluating LP-10 in Subjects With OLP
This is a multicenter, dose-ranging study including adult male and female subjects (>= 18 years old) with symptomatic Oral Lichen Planus (OLP).
- Trial name
- NCT06233591
- Testing
- LP-10 (Liposomal Tacrolimus)
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Lipella Pharmaceuticals, Inc.
Psoriasis
A Study of PRCL-02 in Healthy Volunteers and Plaque Psoriasis
This study consists of three parts: single oral dose escalation in healthy volunteers (Part A), and multiple oral dose escalations in healthy volunteers (Part B) and in participants with chronic plaque psoriasis (Part C)
- Trial name
- NCT03062618
- Testing
- PRCL-02
- Where
- 6 sites in Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- PRCL Research Inc.
Lichen Planus
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
The purpose is to assess the response of subjects to etanercept (as compared to placebo) in treating the physical signs of mucosal and cutaneous lichen planus.
- Trial name
- NCT00285779
- Testing
- Etanercept
- Where
- 12 sites in United States
- Volunteers
- 27 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.